Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.44 USD
-0.02 (-4.09%)
Updated May 24, 2024 04:00 PM ET
After-Market: $0.43 -0.01 (-1.38%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 201 - 212 ( 212 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Clarifies Topical 5% Sildenafil Citrate Cream Phase 2b Trial Clinical Endpoints with the FDA
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WERTHER C
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
Positive Outcome from FDA Meeting Paves Way for Phase 2b FSAD Trial
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
Join in Our Expert Call on Female Sexual Arousal Disorder - Sept. 13
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WERTHER C
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
New Addition to Pipeline Brings Another First-in-Class Potential
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
Early Bird Catches the Worm; Initiating Coverage
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Dare Bioscience, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.